Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 380

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 380
---
578 |

All revenue came from
the sale of services in 2023, 2022 and 2021. It is derived entirely from the Group’s R&D collaboration agreements. It is recognised
over the contract term proportionate to the progress in overall satisfaction of the performance obligations.

| Schedule of performance obligations                                                       |     |                    |     |            |     |            |   |     |                         |   |     |            |   |     |            |   |
|                                                                                           |     | Contractual Assets |     |            |     |            |   |     | Contractual Liabilities |   |     |            |   |     |            |   |
|                                                                                           |     | 2023 £’000         |     | 2022 £’000 |     | 2021 £’000 |   |     |              2023 £’000 |   |     | 2022 £’000 |   |     | 2021 £’000 |   |
| At 1 January                                                                              |     | –                  |     | –          |     |         71 |   |     |                    (197 | ) |     | –          |   |     |        (68 | ) |
| Transfers in the period from contract assets to trade receivables                         |     | –                  |     | –          |     |        (71 | ) |     |                       – |   |     | –          |   |     |          – |   |
| Amounts included in contract liabilities that was recognised as revenue during the period |     | –                  |     | –          |     |          – |   |     |                     197 |   |     | –          |   |     |         68 |   |
| Excess of revenue recognised over cash                                                    |     | –                  |     | –          |     |          – |   |     |                       – |   |     | –          |   |     |          – |   |
| Cash received in advance of performance and not recognised as revenue during the period   |     | –                  |     | –          |     |          – |   |     |                       – |   |     | (197       | ) |     |          – |   |
| At 31 December                                                                            |     | –                  |     | –          |     |          – |   |     |                       – |   |     | (197       | ) |     |          –